These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25756713)

  • 1. [Iron supplementation is recommended in renal anemia].
    Stefansson B
    Lakartidningen; 2015 Mar; 112():. PubMed ID: 25756713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
    Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
    Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.
    Ganz T; Nemeth E
    Semin Nephrol; 2016 Mar; 36(2):87-93. PubMed ID: 27236128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepcidin in chronic kidney disease anemia.
    Santos-Silva A; Ribeiro S; Reis F; Belo L
    Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia in children with chronic kidney disease.
    Greenbaum LA
    Adv Chronic Kidney Dis; 2005 Oct; 12(4):385-96. PubMed ID: 16198278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron Deficiency Anemia in Chronic Kidney Disease.
    Gafter-Gvili A; Schechter A; Rozen-Zvi B
    Acta Haematol; 2019; 142(1):44-50. PubMed ID: 30970355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.
    Ueda N; Takasawa K
    Curr Med Chem; 2017; 24(14):1417-1452. PubMed ID: 28302014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
    Nakanishi T; Kuragano T; Kaibe S; Nagasawa Y; Hasuike Y
    Clin Exp Nephrol; 2012 Dec; 16(6):819-26. PubMed ID: 23053592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease.
    Chand S; Ward DG; Ng ZY; Hodson J; Kirby H; Steele P; Rooplal I; Bantugon F; Iqbal T; Tselepis C; Drayson MT; Whitelegg A; Chowrimootoo M; Borrows R
    J Nephrol; 2015 Feb; 28(1):81-8. PubMed ID: 24687402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale.
    Ratcliffe LE; Thomas W; Glen J; Padhi S; Pordes BA; Wonderling D; Connell R; Stephens S; Mikhail AI; Fogarty DG; Cooper JK; Dring B; Devonald MA; Brown C; Thomas ME
    Am J Kidney Dis; 2016 Apr; 67(4):548-58. PubMed ID: 26763385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between hepcidin level and renal anemia.
    Yang LN; Zhang P; Tang F; Wang G; Li FE
    Genet Mol Res; 2014 Sep; 13(3):7407-10. PubMed ID: 25222239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study.
    Aydin Z; Gursu M; Karadag S; Uzun S; Sumnu A; Doventas Y; Ozturk S; Kazancioglu R
    Ren Fail; 2014 Sep; 36(8):1253-7. PubMed ID: 25040737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Iron therapy in chronic kidney disease].
    Graczyk M; Kohmann A
    Wiad Lek; 2016; 69(5):749-752. PubMed ID: 28033601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of iron deficiency in predialysis state by low molecular weight iron dextran high doses intravenously].
    Fievet P; Coppin M; Brazier F; Lefèvre M; Stephan R; Demontis R
    Nephrol Ther; 2012 Feb; 8(1):41-6. PubMed ID: 21684231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
    Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
    Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.